Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 224 of 6351
-
New hope for Hard-to-Treat colorectal cancer: amivantamab combo enters phase 3
Disease control Recruiting nowThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic a…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Lung cancer trial tests whether chemo before surgery boosts survival
Disease control OngoingThis phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual appro…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Personalizing breast cancer therapy: biomarker test may improve response
Disease control Recruiting nowAdult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Immune booster may strengthen stem cell transplant against hodgkin lymphoma
Disease control Recruiting nowThis is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autolo…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New vaccine aims to outsmart Drug-Resistant lung cancer
Disease control Recruiting nowMulticenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control …
Phase 3 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a shot replace daily HIV pills for those with uncontrolled virus?
Disease control OngoingThis study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their expe…
Phase 3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Heart-Lung machine rescue failing lungs?
Disease control CompletedEvaluation of the efficacy and safety of the Rengine extracorporeal cardiopulmonary support system and the ECMO sterile oxygenator in the management of respiratory failure.
Sponsor: Life Shield Medical Technology Co., LTD • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a maintenance drug extend remission in ovarian cancer? a large Real-World study investigates
Disease control Recruiting now1. Study Introduction This non-interventional real-world study enrolls patients with ovarian cancer who receive niraparib as first-line maintenance therapy under routine clinical care. All patients receive physician-prescribed standard treatment without any study intervention. Th…
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
School lessons could be key to beating cervical cancer in Low-Income nations
Prevention CompletedThe Clinton Health Access Initiative conducted a mixed-methods, school-based interventional study in Cambodia and Kenya to evaluate whether integrating age-appropriate human papillomavirus (HPV) education into existing school health education improves HPV vaccination coverage and…
Sponsor: Clinton Health Access Initiative Inc. • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
Can targeting guilt ease PTSD in veterans?
Symptom relief Recruiting nowThe goal of this clinical trial is to learn if receiving Trauma-Informed Guilt Reduction (TrIGR) Therapy is as effective as receiving Prolonged Exposure Therapy among veterans with PTSD and trauma related guilt. The main questions it aims to answer are: Will TrIGR be comparable …
Sponsor: Veterans Medical Research Foundation • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Triple therapy takes on tough lung cancer
Disease control Recruiting nowBased on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could f…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial
Disease control OngoingThis study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TK…
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immunotherapy combo before surgery shows promise for tough mesothelioma
Disease control Recruiting nowThis phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab,…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in tough lung cancer
Disease control OngoingThis is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed dea…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Could a new pill tame Autism-Related irritability in kids?
Symptom relief Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition…
Phase 3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can a new tracer spot prostate cancer return better than the standard scan?
Diagnosis CompletedThe goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy. The main questions it aims to answer are: * Is there a difference in the number of lesions of prostate cancer recurrence…
Phase 2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can robotic tools make stomach cancer surgery safer and faster?
Disease control Recruiting nowGastric cancer is the fifth most common malignancy and the fourth leading cause of cancer-related deaths. Surgical resection is the primary treatment, with laparoscopic-assisted gastrectomy (LG) being a minimally invasive option. However, LG is limited by restricted instrument mo…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Engineered immune cells take on late-stage lymphoma in new trial
Disease control Recruiting nowSingle-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years.
Phase 2 • Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New stem cell transplant trial aims to treat sickle cell disease and other blood disorders
Disease control Recruiting nowA single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for AML patients? quizartinib trial targets Tough-to-Treat leukemia
Disease control OngoingThis study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC